MyFinsight
Home
Blog
About
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$426,340K
Free Cash flow
-$95,665K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from marketable securit...
Stock-based compensation expense
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepaid expenses and other curre...
Interest receivable and accretio...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-110,736
-102,302
-105,261
-90,896
Interest receivable and accretion of discounts on marketable securities
2,031
877
-687
-177
Depreciation of property plant and equipment
558
587
611
641
Non-cash operating lease expense
325
338
334
330
Deferred income tax recovery
-1,944
447
-1,114
-701
Stock-based compensation expense
16,732
16,894
14,115
13,705
Unrealized foreign exchange gain
458
204
-161
60
Unrealized fair value gain on trading securities
-
-
0
-
Realized (gain) loss on marketable securities
267
400
-18
-89
Other receivables
467
-205
559
-283
Prepaid expenses and other current assets
2,501
1,482
-6,628
3,373
Accounts payable and accrued liabilities
5,716
-1,801
3,193
5,232
Operating lease liability
-358
-349
-335
-337
Other liabilities
41
47
41
3,158
Net cash used in operating activities
-95,390
-88,897
-81,481
-71,752
Purchases of property, plant and equipment
275
133
318
281
Purchases of marketable securities
490,382
505,652
60,900
74,702
Proceeds from marketable securities
159,419
98,503
123,915
113,514
Net cash provided by (used in) investing activities
-331,238
-407,282
62,697
38,531
Proceeds from offerings, net
0
837,526
112,151
-
Proceeds from exercise of stock options
26
5,487
4,962
-
Net cash provided by financing activities
26
843,013
113,537
2,360
Effect of exchange rate changes on cash and cash equivalents
262
-130
-104
-6
Decrease in cash and cash equivalents
-426,340
346,704
94,649
-30,867
Cash and cash equivalents, beginning of period
545,867
199,163
104,514
142,712
Cash and cash equivalents, end of period
119,527
545,867
199,163
104,514
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$26K
Effect of exchange rate
changes on cash and cash...
$262K
(-53.87%↓ Y/Y)
Net cash provided by
financing activities
$26K
(-97.86%↓ Y/Y)
Decrease in cash and cash
equivalents
-$426,340K
(-5715.58%↓ Y/Y)
Canceled cashflow
$288K
Proceeds from marketable
securities
$159,419K
(-52.70%↓ Y/Y)
Stock-based compensation
expense
$16,732K
(-35.37%↓ Y/Y)
Accounts payable and
accrued liabilities
$5,716K
(296.16%↑ Y/Y)
Depreciation of property
plant and equipment
$558K
(-56.78%↓ Y/Y)
Non-cash operating lease
expense
$325K
(-49.92%↓ Y/Y)
Other liabilities
$41K
Net cash provided by
(used in) investing...
-$331,238K
(-383.67%↓ Y/Y)
Net cash used in
operating activities
-$95,390K
(24.22%↑ Y/Y)
Canceled cashflow
$159,419K
Canceled cashflow
$23,372K
Purchases of marketable
securities
$490,382K
(122.85%↑ Y/Y)
Net loss
-$110,736K
(26.05%↑ Y/Y)
Purchases of property,
plant and equipment
$275K
(37.50%↑ Y/Y)
Prepaid expenses and
other current assets
$2,501K
(-61.00%↓ Y/Y)
Interest receivable and
accretion of discounts on...
$2,031K
(131.22%↑ Y/Y)
Deferred income tax
recovery
-$1,944K
(-40.56%↓ Y/Y)
Other receivables
$467K
(222.89%↑ Y/Y)
Unrealized foreign
exchange gain
$458K
(1535.71%↑ Y/Y)
Operating lease liability
-$358K
(42.72%↑ Y/Y)
Realized (gain) loss on
marketable securities
$267K
(151.54%↑ Y/Y)
Buy us a coffee